GILD - Gilead Sciences, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—General
Foster City,
United States
Type: Equity
GILD price evolution
GILD
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2772 | $4718 | $6085 | |
| Short term investments | $1179 | |||
| Net receivables | $4587 | $4663 | $4669 | $4660 |
| Inventory | $3435 | $2026 | $1853 | $1787 |
| Total current assets | $13059 | $12317 | $14041 | $16085 |
| Long term investments | $1163 | |||
| Property, plant & equipment | $5391 | $5346 | $5321 | $5317 |
| Goodwill & intangible assets | $31146 | $31742 | $34768 | |
| Total noncurrent assets | $41262 | $42251 | $46040 | |
| Total investments | $2342 | |||
| Total assets | $54525 | $53579 | $56292 | $62125 |
| Current liabilities | ||||
| Accounts payable | $537 | $622 | $550 | |
| Deferred revenue | ||||
| Short long term debt | $1810 | $3667 | $1798 | |
| Total current liabilities | $11725 | $10781 | $13015 | $11280 |
| Long term debt | $21540 | $21527 | $23189 | |
| Total noncurrent liabilities | $24601 | $25822 | $28096 | |
| Total debt | $23350 | $25194 | $24987 | |
| Total liabilities | $36135 | $35382 | $38753 | $39376 |
| Shareholders' equity | ||||
| Retained earnings | $11165 | $10656 | $16304 | |
| Other shareholder equity | $18390 | $93 | $69 | $28 |
| Total shareholder equity | $18281 | $17539 | $22833 | |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $6085 | $5412 | $5338 | $5997 |
| Short term investments | $1179 | $973 | $1182 | $1411 |
| Net receivables | $4660 | $4777 | $4493 | $4892 |
| Inventory | $1787 | $2820 | $1618 | $1683 |
| Total current assets | $16085 | $15227 | $14772 | $15996 |
| Long term investments | $1163 | $1245 | $1309 | $502 |
| Property, plant & equipment | $5317 | $5475 | $5121 | $4967 |
| Goodwill & intangible assets | $34768 | $37208 | $41787 | $41234 |
| Total noncurrent assets | $46040 | $48728 | $53180 | $52411 |
| Total investments | $2342 | $2218 | $2491 | $1913 |
| Total assets | $62125 | $63171 | $67952 | $68407 |
| Current liabilities | ||||
| Accounts payable | $550 | $905 | $705 | $844 |
| Deferred revenue | ||||
| Short long term debt | $1798 | $2273 | $1516 | $2757 |
| Total current liabilities | $11280 | $11237 | $11610 | $11397 |
| Long term debt | $23189 | $22957 | $25179 | $28645 |
| Total noncurrent liabilities | $28096 | $30725 | $35278 | $38789 |
| Total debt | $24987 | $25230 | $26695 | $31402 |
| Total liabilities | $39376 | $41962 | $46888 | $50186 |
| Shareholders' equity | ||||
| Retained earnings | $16304 | $15687 | $16324 | $14381 |
| Other shareholder equity | $28 | $21209 | $83 | -$60 |
| Total shareholder equity | $22833 | $21240 | $21069 | $18202 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $7545 | $6954 | ||
| Cost of revenue | $1544 | |||
| Gross Profit | $5971 | $5410 | ||
| Operating activities | ||||
| Research & development | $1351 | |||
| Selling, general & administrative | $1377 | |||
| Total operating expenses | $2786 | $2766 | ||
| Operating income | $2644 | |||
| Income from continuing operations | ||||
| EBIT | $2289 | |||
| Income tax expense | -$297 | $438 | ||
| Interest expense | -$238 | $237 | ||
| Net income | ||||
| Net income | $1253 | $1614 | ||
| Income (for common shares) | $1614 | |||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $27116 | $27281 | $24689 | |
| Cost of revenue | $6498 | $5657 | $4572 | |
| Gross Profit | $20618 | $21624 | $20117 | |
| Operating activities | ||||
| Research & development | $5718 | $4977 | $5039 | |
| Selling, general & administrative | $6090 | $5673 | $5151 | |
| Total operating expenses | $13013 | $14294 | $16046 | |
| Operating income | $7605 | $7330 | $4071 | |
| Income from continuing operations | ||||
| EBIT | $7856 | $6775 | $2687 | |
| Income tax expense | $1247 | $1248 | $1580 | |
| Interest expense | $944 | $935 | $984 | |
| Net income | ||||
| Net income | $5665 | $4592 | $123 | |
| Income (for common shares) | $5665 | $4592 | $123 | |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $1614 | -$4170 | $1429 | |
| Operating activities | ||||
| Depreciation | $694 | $690 | $688 | |
| Business acquisitions & disposals | -$152 | -$4043 | -$279 | |
| Stock-based compensation | $210 | $187 | $201 | |
| Total cash flows from operations | $1325 | $2219 | $2169 | |
| Investing activities | ||||
| Capital expenditures | -$130 | -$105 | -$215 | |
| Investments | -$34 | $1938 | -$233 | |
| Total cash flows from investing | -$3224 | -$307 | -$2207 | -$727 |
| Financing activities | ||||
| Dividends paid | -$972 | -$990 | -$943 | |
| Sale and purchase of stock | -$95 | -$254 | -$124 | |
| Net borrowings | -$1851 | $1 | ||
| Total cash flows from financing | -$5693 | -$2953 | -$1361 | -$1099 |
| Effect of exchange rate | $15 | -$11 | -$18 | $37 |
| Change in cash and equivalents | -$1049 | -$1946 | -$1367 | $380 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $5665 | $4592 | $6225 | $123 |
| Operating activities | ||||
| Depreciation | $2693 | $2103 | $2050 | $1480 |
| Business acquisitions & disposals | -$1152 | -$1797 | -$1402 | -$25742 |
| Stock-based compensation | $766 | $637 | $635 | $643 |
| Total cash flows from operations | $8006 | $9072 | $11384 | $8168 |
| Investing activities | ||||
| Capital expenditures | -$585 | -$728 | -$579 | -$650 |
| Investments | -$528 | $60 | -$987 | $11948 |
| Total cash flows from investing | -$2265 | -$2466 | -$3131 | -$14615 |
| Financing activities | ||||
| Dividends paid | -$3809 | -$3709 | -$3605 | -$3449 |
| Sale and purchase of stock | -$768 | -$1087 | -$377 | -$1327 |
| Net borrowings | -$270 | -$1500 | -$4750 | $5684 |
| Total cash flows from financing | -$5125 | -$6469 | -$8877 | $770 |
| Effect of exchange rate | $57 | -$63 | -$35 | $43 |
| Change in cash and equivalents | $673 | $74 | -$659 | -$5634 |
News
Fundamentals
| Market cap | $137.00B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 1.25B |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 7.01% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.72 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.11 |
| Quick ratio | 0.82 |